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Objectives: To analyze whether the introduction of nebulized colistin in patients with chronic 
obstructive pulmonary disease (COPD) and infection with Pseudomonas aeruginosa (PA) is 
associated with a decrease of the number and duration of severe exacerbations.
Materials and methods: Thirty six patients with COPD and infection with PA treated with 
nebulized colistin attending a day hospital during a 5-year (January 2010–December 2014) 
period were prospectively included. Repeated-measures t-tests were used to assess whether 
the introduction of colistin was associated with changes in the number of exacerbations or the 
length of the hospitalizations, comparing for each patient the year prior to the introduction of 
colistin with the year after.
Results: After the introduction of colistin, the number of admissions decreased from 2.0 
to 0.9 per individual year (P=0.0007), and hospitalizations were shorter (23.3 vs 10.9 days, 
P=0.00005). These results persisted when patients with and without bronchiectasis or with and 
without persistence of Pseudomonas were separately analyzed. No pre–post differences were 
detected in the number of exacerbations not requiring admission.
Conclusion: Nebulized colistin seems associated with a strong decrease in the number and 
duration of hospitalizations due to exacerbation in patients with COPD and infection with PA. 
Clinical trials with a larger number of patients are needed in order to confirm these results.
Keywords: bronchiectasis, colistin, COPD, nebulized antibiotics
Introduction
Patients with chronic obstructive pulmonary disease (COPD) often suffer from acute 
exacerbations of their disease, which have a negative impact on quality of life,1 accel-
erate disease progression, and cause increased health care utilization and costs,2,3 
especially in those requiring hospitalization. Evidence suggests that about 50% of these 
exacerbations are attributable to bacteria,4,5 with the most frequently potential patho-
genic microorganisms (PPMs) isolated being Haemophilus influenzae, Streptococcus 
pneumoniae, and Moraxella catharralis,6 while Pseudomonas aeruginosa (PA) is 
usually isolated in subjects with worse forced expiratory volume in 1 second (FEV
1
) 
values with an estimated prevalence between 8%–13%.7,8 The presence of PA infection 
in COPD has also been related to risk factors such as previous hospital admissions, 
use of oral corticosteroids or antibiotics, and the presence of bronchiectasis as well as 
its extent.9–12 It has been demonstrated that a higher mortality after hospital discharge 
is observed in patients with COPD and PA isolation in sputum culture independently 
of other relevant predictors such as age, comorbidity, or BODE (body mass index, 
airflow obstruction, dyspnea, and exercise capacity) index.13 Recent studies demon-
strate that PA has different features in COPD patients, with the most frequent pattern 
being sporadic or intermittent infection.14,15 However, studies based on pulsed-field 
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gel electrophoresis showed a pattern of chronic infection 
with persistent clones similar to cystic fibrosis (CF) in up to 
10% of patients, most of them in severe COPD stages.12,16,17 
Contrary to what occurs in CF, in which the use of long-term 
nebulized antibiotics is accepted, for the treatment of PA 
chronic infection, the management of patients with repeated 
isolates of this PPM is not well established. In this study, we 
investigate the effectiveness of long-term nebulized colistin 
in reducing exacerbation frequency and hospital admissions 
in COPD patients with PA chronic infection.
Methods
study subjects
COPD patients (defined by a FEV
1
/forced vital capacity 
[FVC] below 0.7 in patients with at least 10 pack-years of 
tobacco use according to the Global Initiative for Chronic 
Obstructive Lung Disease criteria) with an FEV
1
 postbron-
chodilatador #50% of the reference value and frequent 
exacerbations (two or more exacerbations in the previous 
year) who are seen at the respiratory day care unit of Hos-
pital Universitari Germans Trias i Pujol for scheduled and 
exacerbation visits.18 Those COPD patients with chronic 
bronchial colonization by PA (at least three consecutive spu-
tum cultures during a 6-month period of stability), or intermit-
tent bronchial colonization (alternating positive cultures with 
negative cultures at least one month apart) are treated with 
nebulized colistin. The eradication protocol when PA was 
first isolated included at least one treatment of 15–21 days of 
antibiotic chosen according to antibiogram. The use of long-
term macrolides was not included in the protocol center, and 
none of these patients followed this treatment.
The study prospectively included 36 consecutive 
subjects with COPD treated with nebulized colistin 
attending a day hospital during a 5-year period (January 2010– 
December 2014). Patients with asthma, malignancy, or 
unstable heart disease were excluded, as were patients with 
a main diagnosis of bronchiectasis.
study design
The primary endpoint of the study was the number of severe 
exacerbations requiring hospital admissions and their 
duration and, secondarily, the number of mild exacerbations 
not requiring hospitalization, comparing the year prior to 
starting nebulized colistin with the year after the begin-
ning of the treatment. Data about COPD exacerbations was 
thoroughly investigated on many fronts, including a review 
of hospital and outpatient medical records, computerized 
databases, and, when necessary, telephone contact with 
the patient or his/her relatives or primary care physician. 
COPD exacerbation was defined as an acute worsening of 
respiratory symptoms resulting in additional therapy, it was 
classified as moderate when the prescription of courses of 
antibiotics and/or oral corticosteroids was required, and it 
was considered severe when patient required hospitalization 
or visited the emergency room.18
At baseline, smoking history, severity of the disease, 
airflow obstruction, comorbidities (Charlson Comorbidity 
Index), use of long-term home oxygen therapy, use of 
ongoing inhaled therapy, and short-term treatments with 
antibiotics and corticosteroids due to respiratory causes in the 
previous year were recorded. The diagnosis of bronchiectasis 
was based on chest high-resolution computed tomography 
scan. High-resolution images were obtained in full inspiration 
at 1 mm collimation and 10 mm intervals from the apex to 
the base of the lungs. The diagnosis of bronchiectasis was 
based on criteria published by Naidich et al.19
nebulization technique
One million international units of colistin in 1 mL 0.45% saline 
was administered through the I-neb adaptive aerosol delivery 
device (Philips Respironics, Chichester, UK). The I-neb is a 
unique device that monitors the time and peak flow of the first 
three breaths during nebulization and then pulses aerosol at 
the start of the inspiratory phase to optimize drug delivery. 
The first dose was administered under supervision, and 2 
weeks after the start of treatment a review of the nebulization 
technique was made. Further, the drug was self-administered 
twice a day. Adherence was evaluated using dispensing data 
of colistin from the hospital pharmacy and directly from the 
patient at every 2 month scheduled visit. We did not evaluate 
direct compliance data using the specific software for use with 
the I-neb AAD System. Only patients who completed at least 
3 months of treatment were included in the analysis.
Bacteriological assessment
Sputum samples were collected from all patients when able to 
produce it during the treatment period at every 2 month sched-
uled visit and for each acute exacerbations of COPD before 
antibiotic administration, and these samples were processed 
locally for Gram stain and semiquantitative bacteriological 
culture. Identification and antibiogram were performed on 
all bacterial isolates following standardized microbiological 
protocols.20 Colistin was routinely tested in all Gram-negative 
bacteria by disk diffusion in enterobacteriaceae and by VITEK 
(biomerieux, Marcy-l’Étoile, France) in nonfermenters. Resis-
tance was only reported in bacteria known as constitutively 
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resistant. Eradication of PA was defined as one year of 
follow-up without PA isolation in good quality sputum.
statistical analysis
Repeated-measures t-tests were used to assess whether there 
were statistically significantly pre–post differences in the num-
ber of exacerbations not requiring admission, the number of 
admissions, and the length of the admissions. These differences 
had been previously checked to be approximately normally dis-
tributed (Shapiro–Wilk test P-values .0.367). The Student’s 
t-tests were separately conducted for the overall sample and 
for the subsamples of patients with and without bronchiectasis. 
Additionally, linear regressions on the differences were used 
to assess whether the effects of treatment might depend on 
COPD severity, on FEV
1
%, and on the number of lobes with 
bronchiectasis (in patients with bronchiectasis).
ethical considerations
The research protocol was approved by the regional ethics 
committee (Ethics Committee for Clinical Research of the 
Hospital Germans Trias i Pujol). All patients provided written 
informed consent to be included in this research.
Results
Thirty-six patients were included in the analysis. Baseline 
characteristics of these patients can be seen in Table 1. 
Bronchiectasis was detected on high-resolution computed 
tomography in 27 of the 36 patients (75%). These patients did 
not show differences in baseline characteristics when com-
pared with those without bronchiectasis, except for a lower 
FEV
1
 postbronchodilation (Table 2). No multidrug-resistant 
PA strains were observed, although in some cases there was 
resistance to quinolones. The average treatment duration was 
10.7±4.2 months. A total of six patients discontinued treatment 
(16.6%). Four patients reported bronchospasm (11.1%) and 
three of them discontinued for this reason (8.4%). There were 
two deaths (5.5%), both after the follow-up year, and so these 
were considered unlikely related to the treatment (1 COPD 
exacerbation, 1 pneumonia). One patient stopped treatment 
because of their own decision (2.8%). Eradication of PA was 
observed in 14 patients (38.9%). No differences in the culture 
results during follow-up were found between patients with and 
without bronchiectasis (Table 3). Resistance to colistin was 
only reported in bacteria known as constitutively resistant.
The number of admissions was found to decrease from 
2.0 before the treatment to 0.9 after the treatment (t=3.7, 
df=35, P=0.0007), and these were shorter (23.3 days before 
the treatment, 10.9 days after the treatment, t=4.7, df=35, 
P=0.00005). These results persisted when patients with and 
without bronchiectasis were separately analyzed. Specifi-
cally, the number of admissions decreased from 2.0 to 1.0 in 
patients with bronchiectasis (t=3.2, df=26, P=0.003) and from 
2.0 to 0.8 in patients without bronchiectasis (t=1.8, df=8, 
P=0.111). Similarly, the length of the admissions decreased 
from 24.1 to 12.0 days in patients with bronchiectasis (t=3.8, 
df=26, P=0.0008) and from 20.8 to 7.8 days in patients 
without bronchiectasis (t=2.6, df=8, P=0.031). No pre–post 
differences were detected in the number of moderate exac-
erbations not requiring admission (Table 4).
The effects of treatment were not found to depend on 
COPD severity, on FEV
1
%, or on the number of lobes with 
bronchiectasis.
Discussion
This study shows that the use of long-term nebulized colistin 
is associated with a decrease in the number and length of 




gender male, n (%) 36 (100)
age (years), m (sD) 72.7 (2.1)
Current smoking, n (%) 0 (0)
Pack-years, m (sD) 41 (4.5)
FeV1 post-BD, (l), m (sD) 1.15 (0.3)
FeV1 post-BD, (% predicted), m (sD) 38 (2)
Charlson Comorbidity Index, m (sD) 3.08 (1.54)
Daily treatments, n (%)




hospitalizations due to aeCOPD/past year, m (sD) 2 (0.27)
Days of hospital stay/past year, m (sD) 23.3 (3.4)
ambulatory aeCOPD/past year, m (sD) 1.7 (0.26)
CT scan findings
Patients with bronchiectasis, n (%) 27 (75)










Abbreviations: COPD, chronic obstructive pulmonary disease; Pa, Pseudomonas 
aeruginosa; sD, standard deviation; FeV1, forced expiratory volume in one second; 
BD, bronchodilator; laMa, long-acting anti-muscarinic; laBa, long-acting b-agonist; 
ICs, inhaled corticosteroids; lTOT, long-term oxygen therapy; aeCOPD, acute 
exacerbation of chronic obstructive pulmonary disease; CT, computed tomography.





hospitalizations due to exacerbation in patients with COPD 
and chronic infection with PA independently of the presence 
or not of bronchiectasis.
The use of different regimes of long-term antibiotic pro-
phylaxis has been proposed in COPD patients with frequent 
bacterial exacerbations, especially those with chronic bronchial 
infection, as a strategy to prevent exacerbations by reducing 
the bacterial load and/or by preventing the acquisition of new 
strains.21 The most common regimens accepted are continuous 
administration of oral macrolides and intermittent oral quino-
lones in selected patients and under strict clinical control.22 
Long-term inhaled antibiotics are an attractive alternative in 
patients with COPD with frequent exacerbations. The rationale 
for nebulized antibiotic therapy is to maximize drug delivery to 
the respiratory airways and limit the potential for systemic side 
effects, and this has demonstrated its benefit in the treatment of 
respiratory chronic infection in CF bronchiectasis.23 Although 
CF remains the only pulmonary condition in which inhaled 
antibiotics have received US Food and Drug Administration 
and European Medicines Agency approval, there is a growing 
interest in the used of this therapy in other conditions outside 
of CF, such as non-CF bronchiectasis (NCFB) and COPD. 
These respiratory tract conditions can present characteristics of 
persistent or recurrent infection of the airway by bacteria such 
as H. influenzae or PA that contribute to the chronic cycle of 
infection and inflammation.24,25 PA is found in approximately 
25% of patients with NCFB, and it has been associated with 
more frequent exacerbations, faster disease progression, and 
increased mortality.11,24,26 Because of the worse clinical out-
comes associated with chronic infection with PA, the British 
Thoracic Society guidelines on bronchiectasis recommend the 
prescription of nebulized antibiotics in such patients if they 
have a high infection frequency.27 Such a recommendation is 
supported by several studies evaluating different nebulized 
antibiotics. A recent meta-analysis performed to determine the 
efficacy and safety of long-term inhaled antibiotics for patients 
with NCFB included nine studies, 5 on inhaled aminoglyco-
side, 2 on inhaled ciprofloxacin, and 1 on inhaled colistin, and 
demonstrated the reduction of sputum bacterial density and the 
increase of eradication of PA. Moreover, nebulized therapy 
decreased risk of exacerbations but failed to improve FEV
1
 and 
St. George’s Respiratory Questionnaire (SGRQ) score.28
To date, there have been only few published reports 
examining the effects of inhaled antibiotics on health out-
comes in COPD. Dal Negro et al29 examined the effect of 
nebulized tobramycin twice a day for 14 days in 13 patients 
with severe COPD colonized by multiresistant PA. The 
authors found a reduction in local inflammation and bacterial 
load (and even eradication in some patients), and finally a 
42% reduction in severe exacerbations after 6 months of treat-
ment. Steinfort et al30 studied the effect of nebulized colistin 
during 18 months in patients chronically infected by Gram-
negative bacteria (14 idiopathic bronchiectasis, 4 severe 
COPD). The authors observed significantly slower decline 
of FEV
1
 and FVC and an improvement in patient-reported 
quality of life.30 In a pilot study conducted at a day hospital 






subjects, n 27 9 –
gender male, n (%) 27 (100) 9 (100) 1
age (years), m (sD) 72.2 (1.8) 74.4 (2.3) 0.53
Current smoking, n (%) 0 (0) 0 (0) 1
Pack-years, m (sD) 37.4 (4.3) 55.0 (34.4) 0.08
FeV1 post-BD, (l), m (sD) 1.06 (0.07) 1.43 (0.21) 0.04
FeV1 post-BD, (% predicted), m (sD) 36.4 (2.2) 43.5 (4.3) 0.13
hospitalizations due to aeCOPD/previous year, m (sD) 2 (0.3) 2 (0.8) 1
Days of hospital stay/past year, m (sD) 24.1 (4.0) 20.8 (6.8) 0.68
ambulatory aeCOPD/previous year, m (sD) 1.6 (0.3) 2.2 (0.7) 0.28
Abbreviations: COPD, chronic obstructive pulmonary disease; Pa, Pseudomonas aeruginosa; sD, standard deviation; FeV1, forced expiratory volume in one second; 
BD, bronchodilator; aeCOPD, acute exacerbation of chronic obstructive pulmonary disease.
Table 3 Microbiological evolution during the follow-up year 








Pa, n (%) 17 (62) 5 (55) 0.17
nonfermenting 
gram-negative,a n (%)
2 (7.4) 0 0.30
Fungal,b n (%) 4 (15) 0 0.13
Notes: anonfermenting gram-negative: Acinetobacter baumannii, Achromobacter 
xylosoxidans, Burkholderia cepacia, Stenotrophomonas maltophilia. bFungal: Aspergillus 
fumigatus.
Abbreviation: Pa, Pseudomonas aeruginosa.




effectiveness of treatment with nebulized colistin
unit specializing in patients with severe and very severe 
COPD and a high risk of exacerbations by PA, the use of 
nebulized colistin was associated with a significant reduction 
in the number of exacerbations and emergency visits during 
a year of follow-up.31
Although those studies have many limitations, includ-
ing their open-label design and their small size, all of them 
suggest a therapeutic role for inhaled antibiotics in COPD 
patients. However, a phase II study investigating the efficacy 
of MP-376 (levofloxacin inhaled solution) in COPD patients 
at high risk for exacerbations failed to demonstrate a sig-
nificant reduction in the exacerbation rate or an increase in 
the time to the next exacerbation compared with placebo.32 
Probably the treatment duration employed in this study 
(5 days every 28 days for 9–12 cycles) may have been sub-
optimal in a population of patients with chronic infection.33
Our study is the first one assessing the effect of long-
term inhaled antibiotic in an extended cohort of patients 
with severe COPD patients who present with repeated 
isolates of PA despite having been treated at least once 
with antibiotic therapy with eradicating intention based on 
antibiogram. These patients presented during the previous 
year frequent exacerbations and included those requiring 
hospitalization with a long average stay. After at least 
6 months of treatment with nebulized colistin the number 
and length of hospital admissions for COPD exacerbation 
was reduced significantly, although no differences were 
detected in the number of exacerbations not requiring 
admission. These findings are consistent with previous 
reports in NCFB patients.34–36 The effect of treatment was 
observed regardless of the presence of bronchiectasis, 
or of the number of lobes affected. In our cohort, bron-
chiectasis was present in up to 75% of the patients, with 
cylindrical being the more frequent type reported affect-
ing 2 or 3 lobes in most of the cases. This incidence of 
bronchiectasis is a little higher than that reported by other 
authors probably due to the selected population.10–12 The 
relationship between the presence of bronchiectasis and 
PA infection has been evaluated with conflicting results. 
Martínez-García et al,11 in a study assessing risk factors 
for bronchiectasis in COPD patients, found that bronchial 
colonization by PPMs was associated with the presence 
of bronchiectasis, but the presence of PA, in the form of 
either a single isolate or chronic colonization, was not. 
The same results were reported by García-Vidal et al.10 
Gallego et al,12 in one study evaluating the prevalence and 
risk factors for PA in severe COPD patients, observed that 
the isolation of PA was significantly associated with the 
extent of bronchiectasis. However, the presence of chronic 
infection by PA, a situation that occurred in up to 10% of 
subjects, was unrelated to the presence of bronchiectasis. 
These data suggest that although chronic bronchial infec-
tion in COPD patients is very frequently associated with 
bronchiectasis, it is not the only determining factor.
In our study, nebulized colistin has been generally well 
tolerated, and only four patients (11%) presented adverse 
effects such as wheezing and bronchospasm, and only three 
of these patients discontinued treatment. In a previous meta-
analysis where clinical trials with inhaled antibiotics were 
analyzed, a higher incidence of wheezing and bronchospasm 
was described in patients receiving treatment, but this was 
similar to the placebo group and therefore resulted in low 
withdrawal due to these adverse events.28 For this reason, 
patients are often routinely instructed to administer bron-
chodilators before the dose of nebulized colistin.
We observed eradication of PA during one year of 
follow-up in 40% of cases, and no development of resistance 
to colistin was recorded. There are several studies that 
support the efficacy of nebulized colistin to eradicate PA 
in sputum, reaching eradication rates between 20% and 
60%.30,35,37 Nevertheless, our findings suggest that clinical 
benefits of nebulized therapy with colistin are not necessar-
ily related to eradication of PA, but to the decrease in the 
bacterial load in the sputum of these patients.
Table 4 results and comparison between pre- and posttreatment outcomes according to the presence or absence of bronchiectasis
Outcome variables Whole group n=36 According to presence of bronchiectasis
With bronchiectasis n=27 Without bronchiectasis n=9
Prea/postb
colistin
Diff (SD) t35 P-value Pre
a/postb
colistin
Diff (SD) t26 P-value Pre
a/postb
colistin
Diff (SD) t8 P-value
hospitalizations due to 
aeCOPD, m (sD)
2/0.9 -1.1 (1.7) 3.7 0.000 2/1 -1 (1.6) 3.2 0.003 2/0.8 -1.2 (2.0) 1.8 0.11
Days of hospital stay, m (sD) 23/11 -12 (15.9) 4.6 0.000 24/12 -12 (16.6) 2.6 0.000 21/8 -13 (14.9) 2.6 0.03
ambulatory aeCOPD, m (sD) 1.7/1.5 -0.2 (1.9) 0.7 0.50 1.5/1.2 -0.3 (1.9) 0.9 0.61 2.2/2.3 -0.1 (2.0) 0.2 0.87
Notes: aData from the previous year to start colistin. bData at 12 months after the start of colistin.
Abbreviations: sD, standard deviation; aeCOPD, acute exacerbation of chronic obstructive pulmonary disease; Diff, difference.





There are several limitations to this study. First, this is a 
retrospective study. Second, the sample size was small. And 
finally, there was no control group to enable comparison of 
the results. However, our results open the possibility to treat 
the negative clinical condition of chronic bronchial infec-
tion by PA in patients with COPD, which is cause of severe 
exacerbations and has a very negative impact on the evolution 
of the disease, that clinicians find difficult to handle.
Conclusion
In conclusion, this study shows that the use of nebulized 
colistin is associated with a decrease in the number and length 
of hospitalizations due to exacerbation in patients with COPD 
and infection with PA. These findings occurred in patients 
with and without bronchiectasis. Clinical trials in this popula-
tion with a larger number of patients are desirable in order to 
confirm these results. The effect that long-term treatment may 
have on the selection of emerging pathogens should also be 
assessed. And finally, economic studies should be done by 
comparing the economic impact between expenditure arising 
from such long-term treatment with the expenses generated 
by exacerbations and hospital admissions.
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